Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

"D-CHRAMPS syndrome" is a newly identified condition with multiple severe symptoms.

This study identified a specific genetic variant in the CCHCR1 gene that may contribute to alopecia areata through impaired keratinization, suggesting an alternative mechanism beyond autoimmune causes.

This case report highlights that a patient with resistance to thyroid hormone was misdiagnosed as having Graves’ disease, leading to unnecessary radioactive iodine treatment.

This study observed that patients with alopecia areata often have a T-cell receptor repertoire in skin lesions that suggests a specific antigen-driven immune response may be important in the disease's pathogenesis.

In this case report, complete hair regrowth was observed in a patient with autoimmune-related alopecia areata after treatment with a Janus kinase inhibitor, suggesting its potential effectiveness for both genetic and sporadic forms of the condition.

In this case study, a woman with alopecia areata experienced significant hair regrowth after starting ritlecitinib but developed an acneiform eruption, leading to the discontinuation of the drug and subsequent hair loss relapse; the eruption suggests a treatment-limiting adverse effect of JAK inhibitors.

This study found that Ritlecitinib significantly reduced hair loss in patients with alopecia areata by lowering SALT scores at weeks 12 and 24 compared to placebo, with acceptable safety but increased minor side effects like headaches and acne.

PLLA injections can cause hair loss and skin issues.

This article discusses the American Board of Hair Restoration Surgery certification process and its role in recognizing physicians' knowledge and skills, but it reports no new results.

This entry contains no research abstract, so no scientific findings or conclusions are reported.

In this study, researchers found that while the SNP rs6152 is strongly associated with androgenetic alopecia, the GGN triplet repeat is not, suggesting the causative variant is likely a non-coding one.

This study reports the first case of diverse medium-sized visceral arterial aneurysms in a patient with functionally impaired A20, potentially linked to HA20, and its atypical presentation in East Asia.

This article is a statement from Robert Niedbalski, president of the American Board of Hair Restoration Surgery for 2018, and contains no new research findings.

In a mouse hair-growth model, this study found that the optimized compound 39 matched the efficacy of pyrilutamide for androgenic alopecia, with faster response and maintained safety, suggesting it as a promising topical AR antagonist with reduced systemic toxicity risk.

This report details the first examination for the American Board of Hair Restoration Surgery, where 27 out of 32 candidates passed both parts of the test, but it presents no new research findings.

This study demonstrated that the Alopecia Areata Disease Activity Index (ALADIN), a new biomarker, strongly correlates with treatment response in patients using JAK inhibitors for alopecia areata.

This study reports a novel missense mutation in the HR gene in a 68-year-old Hungarian woman with alopecia universalis and limb deformities, suggesting a need for further research on its role in these conditions.

This study suggests that rapamycin, but not acarbose, can delay age-related loss of cochlear outer hair cells in UM-HET3 mice at doses that increase life span.

This study found that deferoxamine may protect against sensorineural hearing loss by reducing oxidative stress-induced hair cell death through iron chelation and activation of the Nrf2 signaling pathway in lab models.

This article discusses hair loss disorders, underscoring the recent therapeutic advance of ritlecitinib, approved for severe alopecia areata in individuals aged 12 and older, and the ongoing need to manage expectations given limited treatment options.

This study reports that a novel frameshift mutation in the HTRA1 gene in a CARASIL pedigree led to reduced HTRA1 protein and increased TGF-β1 expression, potentially causing severe CARASIL and peripheral small arterial disease.

Certain gene variations are significantly linked to hair loss, especially in white people.

In this retrospective study, baricitinib and ritlecitinib showed similar effectiveness and safety over 52 weeks for treating severe alopecia areata, with non-severe adverse events more common for baricitinib, driven by weight gain.

This meta-analysis suggests that the G allele of AR StuI polymorphism might be a potential risk factor for AGA, particularly in white populations.

This article presents a dissenting opinion, arguing that the case described by Dr. Molina et al. was diffuse alopecia areata, not acute alopecia areata as claimed, emphasizing the importance of distinct clinical differences.

This study found that upadacitinib significantly improved hair regrowth compared to placebo in adults and adolescents with severe alopecia areata, and demonstrated a positive benefit-risk profile.

In this study, a newly designed protein degrader targeting androgen receptors showed promise in reversing hair regrowth inhibition in a mouse model of androgenetic alopecia, suggesting potential as a novel and safe treatment strategy.

This study evaluates the efficacy and safety of a higher dose (100-mg) of ritlecitinib for treating severe alopecia areata, comparing it to external and synthetic placebo control groups.

This study observed that the rs231775 CTLA4 genetic variant was more prevalent in Alopecia Areata patients than controls, particularly among those with severe disease.

This study investigated the role of NLRP3 inflammasomes in alopecia areata and found that outer root sheath cells may contribute to inflammation by increasing IL-1β and HMGB1 secretion when stimulated with double-stranded RNA.